MS (Multiple Sclerosis) Clinical Trial
Official title:
Effects of Deep Sensory Assisted Rehabilitation on Gait and Balance in Patients With Multiple Sclerosis
Verified date | August 2023 |
Source | Romatem Bursa Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The effect of physical therapy and rehabilitation on improving the gait and balance disorders of patients has been proven. FTR applications in MS patients have become routine in developed countries. However, due to the high patient density in our country, FTR cannot be performed at the rate we want due to different reasons such as the inability to separate areas special for MS patients, the lack of special FTR applications for MS patients, and the inability to perform regular FTR follow-ups. Even if FTR is recommended and performed, our patients think that FTR is not very effective due to the above reasons and they do not continue. A team of neurology, physical therapy specialists, and physiotherapists was formed, in-service training was completed and a special rehabilitation program for MS patients was created. First of all, we will apply routine classical FTR to our patients. Sensory and deep sensory disorders, which are more common and severe, especially in the lower extremities, also negatively affect gait and balance. A rehabilitation program was created by adding exercises to improve sensation and deep sense, along with muscle strengthening. The results of the 1st and 21st sessions of the patients in the two groups who underwent classical rehabilitation and deep sensory-assisted rehabilitation will be compared. It was planned to evaluate the gait and balance parameters of the patients as numerical data with clinical scales and the C mill device we used in walking and balance exercises.
Status | Active, not recruiting |
Enrollment | 40 |
Est. completion date | June 1, 2024 |
Est. primary completion date | February 1, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 20 Years to 60 Years |
Eligibility | Inclusion Criteria: - Diagnosed with multiple sclerosis - 20-60 years old - EDSS between 3.0-5.5 Those with EDSS 0-2.5 and spinal and/or cerebellar involvement - Had the last MS attack at least 3 months ago Exclusion Criteria: - schizoaffective disorder - lower extremity amputation - shortness on one side creating asymmetry in the lower extremities - diabetes mellitus - cognitive impairment (at a level that may interfere with communication) |
Country | Name | City | State |
---|---|---|---|
Turkey | Romatem Physical Therapy and Rehabilitation Hospitals Bursa Hospital | Bursa | |
Turkey | University of Health Sciences Bursa Yuksek Ihtisas Training and Research Hospital | Bursa | Yildirim |
Lead Sponsor | Collaborator |
---|---|
Nermin Çalisir | Bursa Sevket Yilmaz Training and Research Hospital |
Turkey,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Multipl sclerosis quality of life-54(MSQOL-54) | : It is calculated with the combined summary scores of physical and mental health. As the total score increases, the quality of life is evaluated positively. | 1st day: when rehabilitation applications started | |
Primary | Multipl sclerosis quality of life-54(MSQOL-54) | : It is calculated with the combined summary scores of physical and mental health. As the total score increases, the quality of life is evaluated positively. The scale has not minimum and maximum value. The change between the participant's prior and values was evaluated. | after 7 weeks: when rehabilitation applications ended | |
Primary | MiniBest test | minimum and maximum score: 0-28: high score indicates good functional balance | 1st day: when rehabilitation applications started | |
Primary | MiniBest test | minimum and maximum score: 0-28: high score indicates good functional balance | after 7 weeks: when rehabilitation applications ended | |
Primary | 10 meter walking time | The patient's walking time of the determined 10-meter distance is measured. | 1st day: when rehabilitation applications started | |
Primary | 10 meter walking time | The patient's walking time of the determined 10-meter distance is measured. | after 7 weeks: when rehabilitation applications ended | |
Primary | Nottingham Extended Activities of Daily Living Scale | minimum and maximum score: 0-66: high score indicates no restriction in activities of daily living. | 1st day: when rehabilitation applications started | |
Primary | Nottingham Extended Activities of Daily Living Scale | minimum and maximum score: 0-66: high score indicates no restriction in activities of daily living. | after 7 weeks: when rehabilitation applications ended | |
Primary | Functional Ambulation Classification | minimum and maximum score :0-5: high score indicates that walking can be done independently. | 1st day: when rehabilitation applications started | |
Primary | Functional Ambulation Classification | minimum and maximum score :0-5: high score indicates that walking can be done independently. | after 7 weeks: when rehabilitation applications ended | |
Primary | Fatigue Severity Score | A score lower than 2.8 indicates no fatigue, a score higher than 6.1 indicates chronic fatigue | 1st day: when rehabilitation applications started | |
Primary | Fatigue Severity Score | A score lower than 2.8 indicates no fatigue, a score higher than 6.1 indicates chronic fatigue | after 7 weeks: when rehabilitation applications ended | |
Primary | DN4(Douleur Neuropathique 4 Questions) | Minimum and maximum score: 0-10: A score of 4 and above indicates neuropathic pain. | 1st day: when rehabilitation applications started | |
Primary | DN4(Douleur Neuropathique 4 Questions) | Minimum and maximum score: 0-10: A score of 4 and above indicates neuropathic pain. | after 7 weeks: when rehabilitation applications ended | |
Primary | MSWS-12( MS walking scale-12) | minimum and maximum scores: 12-54: low scores indicate that gait disturbance has little effect on disability. | 1st day: when rehabilitation applications started | |
Primary | MSWS-12( MS walking scale-12) | minimum and maximum scores: 12-54: low scores indicate that gait disturbance has little effect on disability. | after 7 weeks: when rehabilitation applications ended | |
Primary | FES-1: (Falls Efficay Scale-1) | minimum and maximum score: 16-64: higher score indicates increased anxiety about falling | 1st day: when rehabilitation applications started | |
Primary | FES-1: (Falls Efficay Scale-1) | minimum and maximum score: 16-64: higher score indicates increased anxiety about falling | after 7 weeks: when rehabilitation applications ended |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04530955 -
Transitioning to a Valve-Gated Intrathecal Drug Delivery System (IDDS)
|
N/A | |
Completed |
NCT05435404 -
Qualitative Study Patient & Physician Experiences Botox COVID-19
|
||
Completed |
NCT04379661 -
SUNLIGHT Study: Online Support Groups for MS to Address COVID-19
|
N/A | |
Recruiting |
NCT05912595 -
EXOPULSE Mollii Suit, Spasticity, Muscular Oxygenation & Multiple Sclerosis (ENNOX 2)
|
N/A | |
Completed |
NCT06199219 -
Ex-Plissit Model Based Counseling on Sexual Function and Sexual Satisfaction
|
N/A | |
Not yet recruiting |
NCT04822623 -
Imaging Evaluation of Central Nervous Autoimmune Diseases
|
||
Completed |
NCT04095377 -
Development of Automated Analysis to Electroencephelogram (EEG) Data in Patients Treated at the Sagol Hyperbaric Medicine and Research Center at the Years 2017-2019.
|
||
Recruiting |
NCT05857280 -
EXOPULSE Mollii Suit, Motor Function & Multiple Sclerosis (EXOSEP 2)
|
N/A | |
Completed |
NCT02490943 -
A Pilot Study of Warm and Cold Compress to Reduce Injection Site Erythema Due to Peginterferon-beta-1a in MS
|
N/A | |
Completed |
NCT01628276 -
Brain Functional Connectivity Changes Following Cognitive Rehabilitation in Multiple Sclerosis: an fMRI Study
|
N/A | |
Recruiting |
NCT03155334 -
Understanding Evaluation of Patient Information Sheets by User Testing Method
|
N/A | |
Completed |
NCT00872053 -
Effect of Robot-assisted Training on Foot Drop in Multiple Sclerosis
|
Phase 1/Phase 2 |